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ABSTRACT 
The objective of the present work was to formulate and characterize floating drug delivery system of Prasugrel hydrochloride that releases the 
drug slowly up to 8 h in order to minimize its potential side effect bleeding and to improve the bioavailability with enhance patient compliance. 
Prasugrel floating tablets were prepared  by effervescent approach with melt granulation and direct compression techniques alone and in 
combination using Hydroxypropyl methylcellulose (HPMC) K100M and Compritol 888 ATO at different concentrations (20%, 30% and 40% 
w/w) alone and in combination. Sodium bicarbonate at concentration 10% w/w was optimized as gas generating floating agent. Evaluations 
were carried out on physical parameters, floating behavior and influence of type of polymer on drug release rate. All the formulations were 
subjected to various quality control and in-vitro dissolution studies and corresponding dissolution data were fitted to popular release kinetic 
equations in order to evaluate release mechanisms and kinetics. All the prasugrel floating tablet formulations followed zero order kinetics. As 
per Korsmeyer-Peppas equation, the release exponent “n” ranged 0.550-0.776 indicating that drug release from all the formulations was by 
non-Fickian diffusion mechanism. Based on the results, prasugrel hydrochloride floating tablets prepared by employing combination of 15% 
w/w HPMC K100M and 15% w/w Compritol 888 ATO offered desired in-vitro floating time and drug dissolution profile. 
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INTRODUCTION 
Oral controlled drug delivery systems with ability to retain in 
gastric region for several hours and prolong the gastric 
residence time of drug are called gastro-retentive drug 
delivery system (GRDDS). These systems offer increased 
therapeutic efficacy of drugs by continuously releasing the 
drug for an extended period at the desired rate with targeted 
delivery in the stomach that improves drug absorption with 
improved patient compliance [1, 2].  
Solubility of drugs those are less soluble in an elevated pH 
environment of the intestine can be improved by prolonging 
the gastric retention to increase bioavailability. Oral 
sustained-controlled release formulations with additional 
gastric retention property have a lower level of side effects 
by releasing the drug slowly in the stomach for an extended 
period of time and provide their therapeutic effects with 
better control of fluctuations in plasma drug concentration 
[3, 4]. 
The controlled gastric retention of the formulation may be 
achieved by the various approaches such as floatation, 
mucoadhesion, sedimentation, expansion and modified 
shape systems [3]. Among the various approaches, floating 
drug delivery system (FDDS) is one of the potential approach 
for prolonged gastric retention to improve solubility, reduces 
drug waste thereby improves bioavailability for the drugs 
that are less soluble in a high pH environment. FDDS offer 
the most effective and rational protection against early and 
random gastric emptying compared to the other methods 
proposed for prolonging the gastric residence time of solid 
dosage forms. However the gastric retention is influenced by 
many factors such as level of fluids in the stomach, gastric 
mobility, pH and presence of food. These factors are never 
constant and hence the buoyancy cannot be predicted [5, 6].  
Prasugrel is a novel third-generation oral thienopyridine 
mainly used to reduce the risk of thrombotic cardiovascular 
events such as stent thrombosis or myocardial infarctions in 
patients with acute coronary syndrome (ACS). Prasugrel is a 
potent prodrug and inhibits platelet aggregation by an 
irreversible blockade of platelet adenosine diphosphate 
(ADP) P2Y12 receptor. Prasugrel is a BCS class II drug and 
exhibits pH dependent solubility and it is very soluble at low 
pH conditions. After oral adstration, prasugrel is rapidly 
absorbed and hydrolyzed by esterases located in the 
intestine and blood, to a thiolactone intermediate metabolite 
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which subsequently activated by cytochrome P450 (CYP) 
dependent step (predominantly CYP3A and CYP2B6) to 
sulfhydryl active metabolite. The active metabolite binds 
irreversibly to the platelet ADP P2Y12 receptor and inhibits 
platelet activation and aggregation. The active metabolite of 
prasugrel has an elimination half-life of 7 hours with an 
approximate bioavailability of 80%. It is more potent and has 
lower inter-individual variability in platelet response, and 
faster onset of activity compared with Clopidogrel. However, 
the potential side effect of the drug is bleeding, particularly 
gastrointestinal bleeding [7, 8]. 
A sustained release Prasugrel formulation that releases the 
drug slowly at the desired rate to avoid peak levels of the 
active metabolite for maintenance treatment may be desired 
mainly to minimize its potential side effect bleeding and to 
improve the bioavailability with enhance patient compliance. 
Further, hydrophilic polymer, HPMC K100M and 
hydrophobic polymer, Compritol 888 ATO have been 
reported to improve stability of drug in the formulations [9].  
Therefore, an attempt has been made to develop gastro 
retentive floating tablets of prasugrel hydrochloride that 
release the drug locally where it is more soluble or absorbent 
in a sustained form that releases the drug slowly up to 8 h to 
minimize the potential side effect, bleeding and to improve 
the bioavailability by using the polymers HPMC K100M and 
Compritol 888 ATO. 
MATERIALS AND METHODS 
Materials  
Prasugrel hydrochloride (Gift sample from MSN 
Laboratories, Hyderabad), Compritol ATO 888, HPMC 
K100M, Sodium bicarbonate, Microcrystalline cellulose, 
Magnesium stearate, Talc and all other ingredients are of 
laboratory grade.  
Drug-excipient compatibility studies 
Drug-excipient compatibility studies were performed for 
pure drug and physical mixture of optimized formulation of 
drug with polymers. The physical mixture samples were 
subjected to Fourier Transform infrared (FT-IR) studies. 
Spectra of drug and optimized formulation were taken and 
analyzed for any major interaction due to presence of 
polymers and other ingredients. 
Micromeritic properties 
The pure drug and prepared formulation powder blends 
were evaluated for micromeritic properties such as angle of 
repose (), bulk density (BD), tapped density (TD), Carr’s 
index (CI) and Hausner’s ratio (HR). 
Angle of repose was determined by fixed funnel method by 
placing ten grams of powder blend in a cotton plugged glass 
funnel and then allowed to flow through the funnel orifice by 
removing the cotton plug. The height of the heap (h) formed 
and the radius of the heap (r) was noted. The angle of repose 
was calculated using the formula   = Tan-1 (h/r). 
BD and TD of 10 g of the powder blend were determined by 
using 50 ml graduated cylinder. Based on the initial volume 
occupied by the blend, BD was calculated in g/ml. The 
cylinder containing the blend was tapped until constant 
volume was obtained using bulk density apparatus from a 
height of 2 cm and the TD was calculated in g/ml. The 
percentage compressibility (CI) was calculated from the 
difference between the TD and the BD divided by the TD and 
the ratio expressed as a percentage. The HR is the ratio 
between the TD and BD [10]. 
Determination of lambda (ʎ) max by Ultraviolet–
visible (UV) spectroscopy 
The stock solution (1000 µg/ml) of prasugrel hydrochloride 
was prepared in 0.1N hydrochloric acid (HCl). This solution 
was appropriately diluted with 0.1N HCl to obtain a 
concentration of 10 µg/ ml. The UV spectrum was recorded 
in the range of 200-400 nm on double beam UV 
spectrophotometer. The spectrum and wavelength of 
maximum absorption were recorded. 
Preparation of standard curve 
The stock solution (1000 µg/ml) of prasugrel hydrochloride 
was prepared in 0.1 N HCl and from this 10 ml of solution 
was taken and the volume was adjusted to 100 ml with 0.1N 
hydrochloric acid (100μg/ml). The above solution was 
suitably diluted with 0.1N hydrochloric acid to get the series 
of dilutions containing 10, 20, 30, 40, 50μg/ml of prasugrel 
hydrochloride solutions. The absorbance of these solutions 
were measured at 258 nm against blank i.e. 0.1 N HCl. The 
coefficient of correlation and equation for the line are 
determined. 
Preparation of prasugrel hydrochloride floating tablets 
The prasugrel hydrochloride floating matrix tablets were 
prepared by effervescent approach with hydrophilic 
polymer, HPMC K100M and hydrophobic polymer, Compritol 
888 ATO at varying concentrations (20%, 30%, 40% w/w) as 
shown in the Table 1 along with all other excipients. Sodium 
bicarbonate at concentration 10% w/w was optimized as gas 
generating floating agent and microcrystalline cellulose 
(MCC) was used as diluents. All the ingredients were passed 
through sieve 44. The formulation F1 to F3 were prepared by 
melt granulation method wherein Compritol 888 ATO was 
melted in a porcelain dish on hot plate and weighed drug 
was added to it. The resultant mixture was allowed to 
solidify at room temperature and passed through sieve 30 to 
form granules for compression. The formulations F4 to F6 
were prepared by direct compression method using HPMC 
K100M. The formulations F7 to F9 were prepared by 
combination of Compritol 888 ATO and HPMC K100M 
wherein melt granulation was employed to incorporate the 
drug into Compritol polymer matrix then followed by direct 
compression method using HPMC K100M. The required 
quantities of other ingredients were added to the blend and 
mixed geometrically. The blend was lubricated with 
magnesium stearate and talc. The final blend was 
compressed into tablets using 5 mm size round concave 
single tip punch on multi station rotary compression 
machine.
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Table 1: Composition of prasugrel hydrochloride floating tablets 
Ingredients (mg/tablet) F1 F2 F3 F4 F5 F6 F7 F8 F9 
Prasugrel Hydrochloride 10.98 10.98 10.98 10.98 10.98 10.98 10.98 10.98 10.98 
Sodium Bicarbonate 5 5 5 5 5 5 5 5 5 
Compritol ATO 888 10 15 20 0 0 0 5 7.5 10 
HPMC K100M 0 0 0 10 15 20 5 7.5 10 
Aerosil 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
Magnesium stearate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
MCC 23.02 18.02 13.02 23.02 18.02 13.02 23.02 18.02 13.02 
Total weight 50 50 50 50 50 50 50 50 50 
 
Evaluation of physical parameters of floating matrix 
tablets [5]  
Tablet weight uniformity:  
A total of twenty (20) tablets were weighed individually, 
average weight was calculated and the individual tablet 
weights were compared with the average weight. The tablets 
will meet the USP test if not more than two tablets are 
outside the percentage limit (± 10%) and if no tablets differ 
by more than two times the percentage limit. 
Thickness test: 
The thickness of three (3) randomly selected tablets from 
each formulation was measured with a Vernier calliper scale 
and their thickness was recorded and the average thickness 
along with the standard deviation is reported. 
Hardness test:  
Hardness of the tablet is the force applied across the 
diameter of the tablet to break the tablet. The hardness of 
three (3) tablets was determined using Monsanto hardness 
tester and the average is calculated and reported with the 
standard deviation and expressed in kg/cm2.  
Friability test: 
Six tablets (6) were initially weighed (W0) and transferred 
into Roche friabilator and the friabilator was operated at 25 
rpm for 4 min or run up to 100 revolutions and the tablets 
were again weighed (W). The percentage friability (%F) was 
then calculated by the following equation: %F = (1−W/W0) × 
100 and %F of tablets <1% are considered as acceptable. 
Drug content: 
A total of three (3) tablets were weighed and powdered. The 
quantity of powder equivalent to 10.98 mg of prasugrel 
hydrochloride was dissolved in 100 ml of 0.1 N HCl. Then the 
solution was filtered, diluted suitably and analyzed using an 
UV spectrophotometer at 258 nm. 
In-vitro buoyancy studies 
The in-vitro buoyancy was determined by floating lag-time 
method. The tablets were placed in a 100 ml beaker 
containing 0.1 N HCl. The time required for the tablet to rise 
to the surface and float was determined as floating lag time 
(FLT) and the duration of the time the tablet constantly floats 
on the dissolution medium was noted as the total floating 
time respectively. 
In vitro drug release studies  
The in-vitro drug release study was performed for all the 
formulations using USP Type II dissolution apparatus at 75 
rpm for 8 hours. Tablets were placed in 900 ml of dissolution 
medium i.e. 0.1 N HCl maintained at 37± 0.5℃. Aliquots of 5 
ml were withdrawn at specified intervals of time, filtered and 
replenished with 5 ml fresh dissolution medium. Sample’s 
absorbance was measured at ʎmax 258 nm using UV 
spectrophotometer. The studies were performed in 
triplicate. The cumulative percentage drug released was 
calculated at each time interval using slope obtained from 
the standard curve. 
Kinetic modeling of drug release: The data obtained from 
in vitro drug release studies were fitted to the following 
kinetic equations: 
Zero order release kinetics equation: Qt = Q0+ K0t; Where Qt 
is the amount of drug dissolved in time t, Q0 is the initial 
amount of drug in the solution (most times, Q0 = 0) and K0 is 
the zero order release constant expressed in units of 
concentration/time and graph was plotted for cumulative 
amount of drug released vs. time.   
First order release kinetics equation: Log C = log 
C0−Kt/2.303; where C0 is the initial concentration of drug, k 
is the first order rate constant and t is the time and graph 
was plotted for log cumulative percentage of drug remaining 
vs. time. 
Higuchi equation defines a linear dependence of the active 
fraction released per unit of surface (Q) on the square root of 
time and can be expressed as Q = KH t1/2; Where, KH is the 
release rate constant. This equation describes drug release 
as a diffusion process based on the Fick’s law, square root 
time dependent and graph was plotted for cumulative 
percentage of drug remaining vs. Square root time. 
In order to define a model, which would represent a better fit 
for the formulation, dissolution data were further analyzed 
by Peppas and Korsmeyer equation: Mt/M∞ = Ktn; Where 
Mt/M∞ is a fraction of drug released at time t, K is the 
release rate constant and n is the release exponent. In this 
model, the value of n characterizes the release mechanism of 
drug. For the case of cylindrical tablets, n = 0.45 corresponds 
to a Fickian diffusion mechanism, 0.45 < n < 0.89 to non-
Fickian transport, n = 0.89 to Case II (relaxation) transport, 
and n > 0.89 to super Case II transport. Graph was plotted for 
log cumulative percentage of drug remaining vs. log time and 
first 60% drug release data were fitted in Peppas and 
Korsmeyer model. 
RESULTS AND DISCUSSION 
Calibration curve of prasugrel hydrochloride 
An UV spectro-photometric method was used for estimation 
of prasugrel hydrochloride. A solution of prasugrel 
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hydrochloride (10μg/mL) was scanned in the wavelength 
range of 200-400 nm and found to have maximum 
absorption (λmax) at 258 nm (Fig. 1) [11]. The standard plot 
of prasugrel hydrochloride was prepared in 0.1 N HCl (pH 
1.2) and showed good linearity with R2 value of 0.9998 (Fig. 
2). 
 
Fig. 1: UV scan spectrum curve of prasugrel 
hydrochloride 
 
Fig. 2: Calibration curve of prasugrel hydrochloride at 
258 nm 
Drug-excipient compatibility studies [11] 
The FT-IR spectrum of pure drug was compared with 
optimized formulation. The characteristic peaks which are 
observed for the pure drug in the FTIR spectra (Fig. 3a) were 
also observed for optimized formulation (Fig. 3b) with little 
shifting of peaks suggesting that there is no interaction 
between drug and excipients (Table 2). 
 
Table 2: The Assignments of the FT-IR Absorption characteristic Bands of Prasugrel HCl and optimized formulation. 
Functional group  
Assignment 
Prasugrel Hydrochloride 
(Wavenumber (cm-1)) 
Optimized formulation (F8)  
(Wavenumber (cm-1)) 
(–NH+) stretching 2435.11 2435.17 
(C=O); carboxylate stretching 1757.60 1757.17 
(C=O); cyclopropylcarbonyl stretching 1688.72 1688.84 
(C-H) bending 1492.64 1492.29 
(C-F) stretching 1406.66 1406.61 
(C-N) stretching 1352.61, 1325.02 1352.65, 1324.40 
(C-O) stretching 1212.97, 1233.02 1213.31, 1233.36 
(C-S) stretching 824.01, 757.36 824.25, 757.64 
 
 
 
Fig. 3a: FT-IR spectra of pure prasugrel hydrochloride 
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Fig.  3b: FT-IR spectra of physical mixture of prasugrel hydrochloride formulation F8 blend with HPMC K100M and 
Compritol 888 ATO. 
 
Micromeritic properties 
The micromeritic properties of prasugrel hydrochloride 
pure drug showed passable flow properties and the flow 
properties of the formulation powder blend with diluent, 
glidant and lubricant showed fair flow properties as it is 
observed from the values of CI and angle of repose. The 
micromeritic properties of drug and optimized bath of the 
formulation were shown in Table 3. 
Table 3: Micromeritic properties of drug and 
optimized batch of prasugrel blend 
Parameters Pure drug F8 
Angle of repose 42.61 33.42 
Carr’s index (%) 22.44 18.36 
Hausner’s ratio 1.28 1.22 
 
Evaluation of physical parameters of floating tablets 
All the prepared tablet formulations were tested as per 
official methods for various physical parameters such as 
thickness, weight variation, hardness and friability. Results 
of the physical tests were shown in Table 4. All the 
formulation of tablets showed uniform thickness. The 
hardness of all the formulations was found to be in the range 
of 4-5 kg/cm2. The weight variation of tablet formulations 
was found to be within USP specification. The friability of all 
the tablet formulations was found to be <1% which is an 
indication of satisfactory mechanical resistance of the 
tablets. The tablet formulations showed no evidence of 
capping, cracking, cleavage or breaking after being removed 
from the friabilator. The drug content of the formulations 
was in between 98% and 102%. Hence, all the prasugrel 
floating tablet formulations were of good quality and 
fulfilled the official pharmacopoeial specifications with 
regard to drug content, hardness and friability.
 
Table 4: Physical characteristics of prasugrel floating  tablet formulations 
Formulation 
code 
Thickness(mm)-
(n=3) 
Weight Variation 
(n=20) 
Hardness (kg/cm2) 
(n=3) 
Friability 
(%) 
(n=6) 
Assay (%) 
(n=3) 
F1 2.65±0.02 51.18±1.10 4.16±0.28 0.14 100.50±1.32 
F2 2.63±0.02 50.11±1.06 4.50±0.50 0.13 99.93±1.40 
F3 2.62±0.01 49.94±1.15 4.33±0.28 0.14 100.36±1.92 
F4 2.61±0.02 51.17±1.12 4.66±0.28 0.17 101.00±0.65 
F5 2.61±0.02 50.12±1.11 4.66±0.28 0.16 98.73±0.60 
F6 2.62±0.02 49.22±1.03 4.66±0.57 0.18 101.30±0.75 
F7 2.61±0.01 49.29±1.15 4.33±0.28 0.19 99.46±1.10 
F8 2.62±0.02 50.39±1.14 4.83±0.28 0.16 100.50±1.10 
F9 2.64±0.03 49.76±1.15 4.83±0.28 0.17 100.53±1.10 
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Floating properties of prasugrel floating matrix tablets    
All the tablet formulations were tested for floating properties 
such as floating lag and total floating time. The results of in-
vitro buoyancy study are shown in the Table 5. Sodium 
bicarbonate was used as gas generating agent at 10% w/w 
concentration. The sodium bicarbonate induces CO2 
generation in the presence of acidic dissolution medium (0.1 
N HCl). The gas generated is trapped and protected within 
the gel formed by hydration of the polymer, thus decreasing 
the density of the tablet below 1 gm/ml, and the tablet 
becomes buoyant.  tablet formulations prepared with 
Compritol 888 ATO (F1 to F3) did not show floating 
behaviour because the formulations did not swell and hence 
failed to form a gel and the CO2 generated did not get 
entrapped, thus these formulations failed to float the tablet. 
The total floating time of other formulations (F4 to F9) was 
observed in between 10 to 12 h with floating lag time <1 min 
and showed better and desired floating characteristics. 
Pictorial presentation of in-vitro buoyancy study results of 
optimized formulation (F8) was shown in Figure 4. 
 
Table 5: In-vitro buoyancy data of prasugrel 
floating tablets 
Formulation 
code 
Floating Lag 
Time* (Seconds) 
(n=3) 
Floating time 
(Hours)* 
F1 NF NF 
F2 NF NF 
F3 NF NF 
F4 19.66±0.57 10 
F5 20.33±1.52 >12 
F6 20.66±1.15 >12 
F7 25.66±0.57 10 
F8 26.66±0.57 >12 
F9 27.33±0.57 >12 
*NF- Not Floated 
 
 
Fig. 4: Pictorial presentation of in-vitro buoyancy study of optimized formulation (F8) 
 
In-vitro drug release studies  
In-vitro drug release studies of floating formulations 
revealed that the release of prasugrel hydrochloride from 
different formulations varies with type and composition of 
matrix forming polymers.  
The in-vitro drug release profiles of the F1, F2 and F3 
formulations each had hydrophobic retardant, compritol are 
shown in Figure 5a. The initial 1 h drug release was 39%, 
26% and 16% for F1, F2 and F3 formulations respectively. 
Formulation F1 showed rapid/bust drug release pattern in 
initial hours due to insufficient polymer concentration, in 
which compritol was only 10 mg (20% w/w) and almost 
85% drug was released within 4 h. F2 and F3 formulations 
containing 15 mg (30% w/w) and 20 mg (40% w/w) of 
compritol showed controlled drug release wherein 98 % in 8 
h and 83 % in 8h was released from the respective 
formulations. However, these formulations did not show any 
floating characteristics as the tablet formulations did not 
swell. 
The in-vitro drug release profiles of the F4, F5 and F6 
formulations each had hydrophilic retardant, HPMC K100M 
are shown in Figure 5b. The initial 1 h drug release was 30%, 
16% and 13% for F1, F2 and F3 formulations respectively. 
F4 formulation showed less sustained effect may be as it has 
only 10 mg (20% w/w) polymer concentration and 
sustained the drug release up to 6 h only. F5 formulation 
containing 15 mg (30% w/w) sustained the drug release up 
to 8 h and released 87 % of drug.  The drug release from F6 
formulation containing 20 mg (40% w/w) was slow and 
failed to release the complete drug at 8 h and released 74 % 
only. The formulations (F1, F2, F3) prepared with 
hydrophilic polymer HPMC K100M showed better controlled 
retardation of drug release than the hydrophobic polymer 
compritol 888 ATO formulations (F4, F5, F6) at their defined 
respective concentrations as 83% drug was released in 8 h 
from matrix tablets containing 30% compritol but matrix 
tablets containing 30% HPMC only released 74 % drug at the 
same time. 
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The in-vitro drug release profiles of the F7, F8 and F9 
formulations each had combination of HPMC K100M and 
compritol 888 ATO are shown in Figure 5c. The initial 1 h 
drug release was 34%, 22% and 14% for F7, F8 and F9 
formulations respectively.  F7 formulation showed rapid 
drug release as it has only 5 mg (10% w/w) of compritol and 
5 mg (10% w/w) of HPMC K100M polymer concentration 
and more than 85 % drug was released within 5 h which 
may be due to insufficient polymer concentrations. F8 
formulation released 97% of drug at 8 h whereas the drug 
release from F9 formulation was slow and released only 84 
% of drug in 8 h. Formulation F8 with 7.5 mg (15% w/w) of 
compritol and 7.5 mg (15% w/w) of HPMC K100M polymer 
concentration showed better and desirable complete drug 
release within 8 h with required floating characteristics, 
hence it was considered as an optimized formulation. It was 
noted that incorporation of compritol with HPMC at defined 
respective concentrations, increases the drug release from 
the formulations as compared to HPMC K100M alone 
formulations.
 
 
Fig. 5a: Cumulative percentage drug release of 
formulations with Compritol 888 ATO 
 
 
Fig. 5b: Cumulative percentage drug release of 
formulations with HPMC K100M
 
Fig. 5c: Cumulative percentage drug release of formulations with combination of Compritol 888 ATO and HPMC K100M 
Kinetic modelling of drug release 
Analysis of the drug release data as per zero order and first 
order kinetic models indicated that all the formulations 
followed zero order kinetics and dissolution rate constant 
(K) values were presented in Table 6. In the analysis of 
release data as per Korsmeyer-Peppas equation, the release 
exponent “n” was in the range 0.550-0.776 indicating non-
fickian diffusion as the release mechanism from all the 
prasugrel floating tablets. The drug release rate of prasugrel 
was found to be affected by the type and concentration of 
the polymer used in the formulation. As the concentration of 
the polymer was increased, the drug release was found to be 
retarded.
 
Table 6: Regression coefficient (R2) values of floating tablet formulations for different kinetic models 
Formulation code 
R2 
Peppas (n) 
Zero order rate 
constant (K) Zero First Higuchi Korsmeyer–Peppas 
F1 0.9574 0.8208 0.9911 0.9916 0.649 18.16 
F2 0.9768 0.7644 0.9755 0.9987 0.550 10.81 
F3 0.9938 0.9335 0.9445 0.9902 0.698 9.687 
F4 0.9835 0.698 0.9706 0.9971 0.602 15.30 
F5 0.9965 0.931 0.9329 0.9811 0.722 10.60 
F6 0.9958 0.9556 0.9361 0.994 0.776 8.86 
F7 0.9899 0.8505 0.9915 0.9947 0.575 14.94 
F8 0.9902 0.8148 0.9384 0.9735 0.563 11.15 
F9 0.9925 0.8903 0.9261 0.9939 0.748 9.87 
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CONCLUSION 
In this research work, an attempt has been made to develop 
floating tablets of prasugrel hydrochloride by effervescent 
approach using the polymers HPMC K100M and Compritol 
888 ATO to sustain the drug release properties up to 8 h to 
minimize the potential side effect bleeding and to improve 
the bioavailability. According to the above results, optimised 
floating tablet formulation (F8) prepared by employing 
combination of 15% w/w HPMC K100M and 15% w/w 
Compritol 888 ATO with 10% w/w sodium bicarbonate 
offered desired in-vitro floating time and drug dissolution 
profile and the adopted method yielded uniform and 
reproducible floating matrix tablets.  
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